Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma

Growth Hormone and IGF Research

Volumn 20, Issue 3, 2010, Pages 234-238

  Gigek, Carolina Oliveira ^a   Leal, Mariana Ferreira ^a   Lisboa, Luara Carolina Frias ^a   Silva, Patricia Natalia Oliveira ^a   Chen, Elizabeth Suchi ^a   Lima, Eleonidas Moura ^b   Calcagno, Danielle Queiroz ^c   Assumpção, Paulo Pimentel ^c   Burbano, Rommel Rodriguez ^c   Smith, Marilia de Arruda Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^c FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Gastric cancer; IGFBP 3; Methylation; Protein expression

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH MUCOSA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; PROTEINS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953082600     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.02.005     Document Type: Article

References (39)

1. Bach L.A., Headey S.J., Norton R.S. IGF-binding proteins - the pieces are falling into place. Trends Endocrinol. Metab. 2005, 16:228-234.
2. Perks C.M., Holly J.M. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J. Mammary Gland Biol. Neoplasia 2008, 13:455-469.
3. Furstenberger G., Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol. 2002, 3:298-302.
4. Zhang Z.W., Newcomb P.V., Moorghen M., et al. Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom). Cancer Causes Control 2004, 15:211-218.
5. Grimberg A. p53 and IGFBP-3: apoptosis and cancer protection. Mol. Genet. Metab. 2000, 70:85-98.
6. Yamada P.M., Lee K.W. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am. J. Physiol. Cell Physiol. 2009, 296:C954-C976.
7. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006, 97:64-71.
8. Shon J.K., Shon B.H., Park I.Y., et al. Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res. 2009, 139:14-21.
9. Fridman A.L., Rosati R., Li Q., Tainsky M.A. Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. Biochem. Biophys. Res. Commun. 2007, 357:785-791.
10. Tomii K., Tsukuda K., Toyooka S., et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int. J. Cancer 2007, 120:566-573.
11. Panani A.D. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008, 266:99-115.
12. Li W., Li L., Liu Z., et al. Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues. Cancer Lett. 2008, 260:28-36.
13. Resende A.L.S., Matos I.E., Koifman S. Mortalidade por câncer gástrico no Estado do Pará, 1980-1997. Arq. Gastroenterol. 2006, 43:247-252.
14. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965, 64:31-49.
15. Ponten F., Jirstrom K., Uhlen M. The human protein atlas - a tool for pathology. J. Pathol. 2008, 216:387-393.
16. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93:9821-9826.
17. Takahashi M., Rhodes D.R., Furge K.A., et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. USA 2001, 98:9754-9759.
18. Rocha R.L., Hilsenbeck S.G., Jackson J.G., Lee A.V., Figueroa J.A., Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J. Natl. Cancer Inst. 1996, 88:601-606.
19. Yamazaki K., Sakamoto M., Ohta T., Kanai Y., Ohki M., Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22:847-852.
20. Kettunen E., Anttila S., Seppanen J.K., et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet. Cytogenet. 2004, 149:98-106.
21. Yi H.K., Hwang P.H., Yang D.H., Kang C.W., Lee D.Y. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur. J. Cancer 2001, 37:2257-2263.
22. Lee D.Y., Yi H.K., Hwang P.H., Oh Y. Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochem. Biophys. Res. Commun. 2002, 294:480-486.
23. Hanafusa T., Shinji T., Shiraha H., et al. Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 2005, 5:9.
24. Khayat A.S., Guimaraes A.C., Calcagno D.Q., et al. Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol. 2009, 9:55.
25. Cesar A.C., Borim A.A., Caetano A., Cury P.M., Silva A.E. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet. Cytogenet. 2004, 153:127-132.
26. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
27. Leal M.F., Lima E.M., Silva P.N., et al. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J. Gastroenterol. 2007, 13:2568-2574.
28. Gigek C.O., Leal M.F., Silva P.N.O., et al. hTERT Methylation and Expression in Gastric Cancer. Biomarkers 2009, 14:630-636.
29. Hanafusa T., Yumoto Y., Nouso K., et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002, 176:149-158.
30. Wiley A., Katsaros D., Fracchioli S., Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 2006, 16:210-218.
31. Kawasaki T., Nosho K., Ohnishi M., et al. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia 2007, 9:1091-1098.
32. Ogino S., Meyerhardt J.A., Kawasaki T., et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007, 450:529-537.
33. Chang Y.S., Wang L., Liu D., et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2002, 8:3669-3675.
34. Christoph F., Kempkensteffen C., Weikert S., et al. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Lett. 2007, 247:137-142.
35. Martin J.L., Baxter R.C. Transforming growth factor-beta stimulates production of insulin-like growth factor-binding protein-3 by human skin fibroblasts. Endocrinology 1991, 128:1425-1433.
36. Vagenas K., Spyropoulos C., Gavala V., Tsamandas A.C. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J. Surg. Res. 2007, 139:182-188.
37. Zolota V., Batistatou A., Tsamandas A.C., Iliopoulos G., Scopa C.D., Bonikos D.S. Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study. Int. J. Gastrointest. Cancer 2002, 32:83-89.
38. Sartor R.B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994, 106:533-539.
39. Marshall B. Helicobacter pylori: 20 years on. Clin. Med. 2002, 2:147-152.